Monitor the LB2102 Phase 1 data at ASCO on May 31 for early efficacy/safety signals in solid tumors — positive data could drive a 5-10% move. The CARVYKTI subgroup analyses are incremental and unlikely to move the stock. The investor webcast may provide qualitative commentary on commercial trends.
Price Chart
Executive Summary
Legend Biotech announced it will present preliminary Phase 1 data for LB2102 (DLL3-targeted CAR-T in solid tumors) as a rapid oral presentation at ASCO 2026, along with new CARVYKTI subgroup analyses. This is a routine pipeline update with no financial data or regulatory catalysts — the LB2102 data is early-stage and the CARVYKTI presentations are incremental. The filing is a standard 6-K press release with no material financial impact.
Key Facts
- Preliminary Phase 1 data for LB2102 (DLL3 CAR-T in SCLC/LCNEC) will be presented as a rapid oral presentation at ASCO 2026 on May 31.
- New CARTITUDE-4 cytogenetic subgroup analysis and IEC-EC incidence analysis from CARVYKTI trials will be presented as posters.
- CARVYKTI is commercially available in 18 countries and has treated over 10,000 patients.
- Legend Biotech will host an investor webcast on May 31 at 6:15 p.m. CT.
- No financial results, guidance changes, or regulatory decisions were disclosed.
Financial Impact
No financial figures disclosed. Pipeline update with no revenue or earnings impact.
Risk Factors
- LB2102 is early-stage (Phase 1) with no guarantee of efficacy in solid tumors.
- CARVYKTI safety profile includes boxed warnings for CRS, neurotoxicity, and secondary malignancies — any new safety signals at ASCO could be negative.
- No financial data or guidance in this filing — limited near-term catalyst.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001171843-26-003622 |
| Document: f6k_052126.htm | 0001171843-26-003622 |
| Document: 0001171843-26-003622-index-headers.html | 0001171843-26-003622 |
| Document: 0001171843-26-003622-index.html | 0001171843-26-003622 |
| Document: 0001171843-26-003622.txt | 0001171843-26-003622 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 15, 2026 11d ago | 6-K | $19.80 | awaiting T+20 | — | $20.39 (+2.98%) |
Oct 13, 2026 13d ago | 6-K | $17.88 | awaiting T+20 | — | $20.39 (+14.04%) |
Sep 29, 2026 27d ago | 144 | $18.82 | awaiting T+20 | — | $20.39 (+8.34%) |
Sep 25, 2026 4w ago | 6-K | $19.11 $19.27 | ▲ +0.84% | ▲ +2.31% | $20.39 (+6.70%) |
Sep 25, 2026 4w ago | Press Release | $19.11 $19.27 | ▲ +0.84% | ▲ +2.31% | $20.39 (+6.70%) |
Sep 15, 2026 5w ago | 6-K | $17.67 $17.88 | ▲ +1.19% | ▼ −1.53% | $20.39 (+15.39%) |
Sep 14, 2026 6w ago | 6-K | $18.53 $17.80 | ▼ −3.94% | ▼ −6.20% | $20.39 (+10.04%) |
Aug 11, 2026 10w ago | 6-K | $21.83 $19.91 | ▼ −8.80% | ▼ −7.74% | $20.39 (−6.60%) |
Jul 27, 2026 13w ago | 6-K | $19.27 $20.94 | ▼ −8.67% | ▼ −5.37% | $20.39 (−5.81%) |
Jul 27, 2026 13w ago | Press Release | $19.27 $20.94 | ▲ +8.67% | ▲ +5.37% | $20.39 (+5.81%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers